← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Kenvue, the former J&J consumer health business, agreed to be acquired by Kimberly-Clark while revenue slipped 2.1% to $15.12B and operating margin recovered 405 bps to 15.96%
The read at a glance✓ Audited against SEC data
- Growth — Revenue down 2.1% to $15.12B; organic sales down 2.2% on lower volumesWatch
- Profitability — Operating margin up 405 bps to 15.96%; net income up 42.7% to $1.47BOK
- Balance sheet — Total debt $8.52B, down 1.0%; equity up 11.3% to $10.77BNote
- Accounting quality — Grey-zone balance-sheet screen; no manipulation flag; earnings quality safeNote
- Capital allocation — Dividends $1.58B, $0.825 per share; buybacks $197M, halted under the merger agreementNote
- Pending deal — Kimberly-Clark to pay 0.14625 of its shares plus $3.50 cash per Kenvue shareWatch
Business
Kenvue describes itself as the world's largest pure-play consumer health company by revenue, selling brands such as Tylenol, Listerine, Neutrogena, Aveeno, BAND-AID, Johnson's, Nicorette and Zyrtec in more than 165 countries. It was Johnson & Johnson's consumer health business until its 2023 IPO and full separation. On November 2, 2025 it agreed to be acquired by Kimberly-Clark; shareholders of both companies approved the deal on January 29, 2026, and it is expected to close in the second half of 2026.
Where the revenue comes from
Fiscal 2025, as Kenvue Inc. reports it. History and quarterly detail are in the app.
- Self Care$6.4B
- Essential Health$4.6B
- Skin Health and Beauty$4.1B
Leadership changes
From Kenvue Inc.'s own filings, the day they're filed.
- Heather Howlett · Chief Financial Officer · appointmenteff. 2026-05-12
- Amit Banati · Chief Financial Officer · departureeff. 2026-05-12
- Amit Banati · Chief Financial Officer · departureeff. 2026-05-12
Latest filings
- 8-K · Company announcement2026-10-13
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-05-22
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Kenvue Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.